Effects of simvastatin, pentoxifylline and spironolactone on hepatic fibrosis and portal hypertension in rats with bile duct ligation

Journal of Hepatology

Volumn 26, Issue 6, 1997, Pages 1363-1371

  Oberti, Frédéric ^a   Pilette, Christophe ^a,b   Rifflet, Hervé ^a   Maïga, Moussa Y ^a   Moreau, Alain ^b   Gallois, Yves ^c   Girault, Andrée ^c   Le Bouil, Anne ^c   Le Jeune, Jean Jacques ^c   Saumet, Jean Louis ^c   Feldmann, Gérard ^b   Calès, Paul ^a  

^a UNIVERSITÉ D'ANGERS   (France)

^b INSERM   (France)

^c NONE

Author keywords

Antifibrotic agents; Bile duct ligation; Hepatic fibrosis; Pentoxifylline; Portal hypertension; Porto systemic shunts; Rat; Simvastatin; Spironolactone

Indexed keywords

PENTOXIFYLLINE; SIMVASTATIN; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HEMODYNAMICS; IMAGE ANALYSIS; LIVER FIBROSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RAT;

EID: 0030825512     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80473-4     Document Type: Article

References (51)

1. Lee SS, Hadengue JL, Girod C, Braillon A, Lebrec D. Reduction of intrahepative vascular space in the pathogenesis of portal hypertension. In vitro and in vivo studies in the rat. Gastroenterology. 93:1987;157-161.
2. Takato U, Sadotaka I, Takuyi T, Seishu T, Houhi K, Motoari K. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology. 105:1993;475-481.
3. Peterson TC. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology. 17:1993;486-493.
4. Préaux AM, Mallat A, Dhumeaux D, Mavier P. Pentoxifylline inhibits the proliferation and the fibrogenic properties of human hepatic myofibroblastic cells. Hepatology. 22:1995;280A. (4pt2).
5. Peterson TC, Isbrucker RA. Fibroproliferation in liver disease: role of monocyte factors. Hepatology. 15:1992;191-197.
6. Narayanan AS, Page RC. Biosynthesis and regulation of type V collagen in diploid human fibroblasts. J Biol Chem. 258:1983;11694-11699.
7. Dagenais M, Pomier-Layrargues G, Rocheleau B, Giroux L, Huet PM. Systemic and splanchnic haemodynamic effects of pentifylline in rats with portal hypertension. Clin Sci. 83:1992;41-45.
8. Mallat A, Préaux AM, Blazejewski S, Dhumeaux D, Rosenbaum J, Mavier P. Effects of simvastatin, an inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology. 20:1994;1589-1594.
9. Garcia-Pagan J, Salmeron JM, Feu F, Luca A, Ginés P, Pizcueta P, Claria J, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology. 19:1994;1095-1099.
10. Brilla CG, Weber KT. Prevention of myocardial fibrosis in hypertension: role of fibroblast corticoid receptors and spironolactone. FASEB J. 5:1991;2814-2823.
11. Lebrec D. Animals models of portal hypertension. Okuda K, Benhamou JP. Portal Hypertension: Clinical and Physiological Aspects. 1991;101-113 Springer-Verlag, Tokyo.
12. Ishise S, Pergam BL, Yamamoto J, Kitamura Y, Frohlich ED. Reference sample microsphere method: cardiac outpout and blood flows in conscious rat. Am J Physiol. 239:1980;H443-H449.
13. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portysystemic shunting in experimental portal hypertension. Am J Physiol. 257:1989;G52-G57.
14. James J, Bosch KS, Aronson DC, Houtkooper JM. Sirus red, histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver. 10:1990;1-5.
15. O'Connel DL, Dobson AJ. General observer-agreement measures on individual subjects and groups of subjects. Biometrics. 40:1984;973-983.
16. Bosch J, Enriquez R, Groszmann RJ, Storer EH. Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertensive model. Hepatology. 3:1983;1002-1007.
17. Franco D, Gigou M, Szekely AM, Bismuth H. Portal hypertension after bile duct obstruction. Arch Surg. 114:1979;1064-1067.
18. Pizcueta PM, de Lacy AM, Kravetz D, Bosch J, Rodés J. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotics. Hepatology. 10:1989;953-957.
19. Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology. 14:1991;325-330.
20. Lin HC, Soubrane O, Cailmail S, Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein sternosed rats. J Hepatol. 13:1991;213-219.
21. Sarin SK, Groszmann RJ, Mosca PG, Rojkind M, Stadecker MJ, Bhatnagar R, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest. 87:1991;1032-1036.
22. Bosch J, Mastai R, Kravetz D, Bruix J, Rigau J, Rodés J. Measurement of azygos venous blood flow in the evaluation of portal hypertension patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. J Hepatol. 1:1985;125-139.
23. Poo JL, Feldmann G, Moreau A, Gaudin C, Lebrec D. Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol. 19:1993;90-94.
24. Poo JL, Feldmann G, Erlinger S, Braillon A, Gaudin C, Dumont M, Lebrec D. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology. 102:1992;1752-1759.
25. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol. 65:1984;305-311.
26. Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D. Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis. J Hepatol. 25:1996;79-84.
27. Gressner AM, Meyer D. The role of proteoglycans in liver fibrogenesis. Gressner AM, Ramadori G. Molecular and Cell Biology of Liver Fibrogenesis. 1992;115-1136 Kluver Academic Publishers, Dordrecht.
28. Feldmann G. Critical analysis of the methods used to morphologically quantify hepatic fibrosis. J Hepatol. 22:1995;49-54. (Suppl. 2).
29. Rubio CA, Porwit A. Quantitation of fibrosis in liver biopsies. Anal Quant Cytol Histol. 10:1998;107-109.
30. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WHJ. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Dig Dis. 16:1971;1082-1086.
31. Maharaj B, Leary WP, Naran AD, Mahara RJ, Cooppan RM, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 3:1986;523-525.
32. Tamaki S, Ueno T, Torimura T, Kin M, Sakata R, Sakamoto M, et al. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in liver cirrhosis. Gastroenterology. 110:1996;A1340.
33. Rubio M, Parés A, Gasso M, Gimenez A, Deulofeu R, Caballeria J, Bruguera M, et al. Pentoxifylline prevents liver fibrosis but induces cellular damage in carbon tetrachloride injured rats. J Hepatol. 21:1994;S136.
34. Boick G, Raetsch C, Stroeter L, Waldschmidt J, Herbst H, Riecken EO, et al. Antifibrotic effect of pentoxifylline in rat biliary fibrosis due to bile duct obstruction. J Hepatol. 23:1995;142. (suppll).
35. Hodgson PD, Peterson TC. Effect of pentoxifylline in a heterologous serum model of fibrosis in the rat. Hepatology. 22:1995;429A. (4pt2).
36. Raetsch C, Boigk G, Stroeter L, Waldschmidt J, Herbst H, Riecken EO, et al. Pentoxifyllin inhibits hepatic collagen deposition in early but not advanced rat biliary fibrosis. Gastroenterology. 110:1996;A1301.
37. Davern TJ, Liao X, Ferrell L, Rockey D, Friedman SL, Escabedo JA, et al. Role of platelet-derived growth factor (PDGF) in hepatic fibrosis: evaluation in a novel transgenic mouse model. Hepatology. 22:1995;281A. (4pt2).
38. Wong L, Yamasaki G, Johnson RL, Friedman SL. Induction of β-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest. 94:1994;1563-1569.
39. Sanchez S, Bandi JC, Albornoz L, Cateros G, Mastai R. Pentoxifylline decreases portal pressure by reducing blood viscosity in cirrhotic rats. J Hepatol. 18:1993;S167.
40. Feu F, Garcia-Pagan JC, Ruiz del Arbol L, Cirera I, Pizcueta P, Bosch J. Lack of effect of pentoxifylline on portal pressure and hemodynamics in cirrhosis. Clin Sci. 83:1992;41-45.
41. Bendtsen F, Henriksen J, Sorensen T. Long term effects of oral propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis and oesophageal varices. Scand J Gastroenterol. 26:1991;933-939.
42. Carlberg M, Larson O. Role of N-linked glycosylation in cell-cycle progression and initiation of DNA synthesis in tumor-transformed human fibroblasts. Anticancer-Res. 13:1993;167-171.
43. Brilla CG, Pick R, Tan LB, Janicki TJ, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Cir Res. 67:1990;1355-1364.
44. Brilla CG, Zhou G, Weber KT. Aldosterone-mediated stimulation of collagen synthesis in cultured cardiac fibroblasts. J Hypertension. 10:1992;23. (suppl 4).
45. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovascular Res. 26:1992;671-677.
46. Rombouts K, Niki T, Kormoss N, Geerts A. Effect of aldosterone on extracellular matrix synthesis by hepatic stellate cells. J Hepatol. 25:1996;112. (suppl 1).
47. Colombato LA, Albillos A, Genecin P, Sarin S, Groszmann RJ. Prevention of portal systemic shunting in propranolol-treated and in sodium-restricted cirrhotic rats. Gastroenterology. 100:1990;A730.
48. ω-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology. 105:1993;1464-1470.
49. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol. 86:1991;46-52.
50. Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmac. 92:1987;535-544.
51. Van de Casteele M, Van Roey G, Nevens F, Fevery J. Low doses of spironolactone reduce portal vein pressure without affecting plasma volume in the rat. J Hepatol. 25:1996;90. (suppl 1).